Fluvoxamine in the treatment of panic disorder: A multi-center, double-blind, placebo-controlled study in outpatients

Gregory M. Asnis, Faiq A. Hameedi, Andrew W. Goddard, Steven G. Potkin, Donald Black, Mustaq Jameel, Kishore Desagani, Scott W. Woods

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Serotonergic mechanisms have been implicated in panic disorder, and several preliminary studies suggest that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is helpful in its treatment. This 8-week double-blind parallel-group study compared fluvoxamine with a placebo in 188 patients with DSM-III-R defined panic disorder with or without agoraphobia. Efficacy assessments included a Daily Panic Attack Inventory, the Sheehan Disability Scale, the Clinical Anxiety Scale and the Clinical Global Impression Scale. When compared with the placebo, fluvoxamine produced highly significant improvements in most measures of the frequency and severity of panic disorder and in the more global aspects of disability and distress. Significant improvement was evident as early as week 1 for some panic variables. Fluvoxamine is a potent anti-panic agent with a relatively rapid onset of action.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalPsychiatry Research
Volume103
Issue number1
DOIs
StatePublished - Aug 5 2001
Externally publishedYes

Fingerprint

Fluvoxamine
Panic Disorder
Outpatients
Placebos
Panic
Agoraphobia
Serotonin Uptake Inhibitors
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Anxiety
Equipment and Supplies

Keywords

  • Agoraphobia
  • Anxiety
  • Selective serotonin reuptake inhibitor

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Asnis, G. M., Hameedi, F. A., Goddard, A. W., Potkin, S. G., Black, D., Jameel, M., ... Woods, S. W. (2001). Fluvoxamine in the treatment of panic disorder: A multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Research, 103(1), 1-14. https://doi.org/10.1016/S0165-1781(01)00265-7

Fluvoxamine in the treatment of panic disorder : A multi-center, double-blind, placebo-controlled study in outpatients. / Asnis, Gregory M.; Hameedi, Faiq A.; Goddard, Andrew W.; Potkin, Steven G.; Black, Donald; Jameel, Mustaq; Desagani, Kishore; Woods, Scott W.

In: Psychiatry Research, Vol. 103, No. 1, 05.08.2001, p. 1-14.

Research output: Contribution to journalArticle

Asnis, GM, Hameedi, FA, Goddard, AW, Potkin, SG, Black, D, Jameel, M, Desagani, K & Woods, SW 2001, 'Fluvoxamine in the treatment of panic disorder: A multi-center, double-blind, placebo-controlled study in outpatients', Psychiatry Research, vol. 103, no. 1, pp. 1-14. https://doi.org/10.1016/S0165-1781(01)00265-7
Asnis, Gregory M. ; Hameedi, Faiq A. ; Goddard, Andrew W. ; Potkin, Steven G. ; Black, Donald ; Jameel, Mustaq ; Desagani, Kishore ; Woods, Scott W. / Fluvoxamine in the treatment of panic disorder : A multi-center, double-blind, placebo-controlled study in outpatients. In: Psychiatry Research. 2001 ; Vol. 103, No. 1. pp. 1-14.
@article{5bba9e833d4d4c07b68ca9a1da5d050b,
title = "Fluvoxamine in the treatment of panic disorder: A multi-center, double-blind, placebo-controlled study in outpatients",
abstract = "Serotonergic mechanisms have been implicated in panic disorder, and several preliminary studies suggest that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is helpful in its treatment. This 8-week double-blind parallel-group study compared fluvoxamine with a placebo in 188 patients with DSM-III-R defined panic disorder with or without agoraphobia. Efficacy assessments included a Daily Panic Attack Inventory, the Sheehan Disability Scale, the Clinical Anxiety Scale and the Clinical Global Impression Scale. When compared with the placebo, fluvoxamine produced highly significant improvements in most measures of the frequency and severity of panic disorder and in the more global aspects of disability and distress. Significant improvement was evident as early as week 1 for some panic variables. Fluvoxamine is a potent anti-panic agent with a relatively rapid onset of action.",
keywords = "Agoraphobia, Anxiety, Selective serotonin reuptake inhibitor",
author = "Asnis, {Gregory M.} and Hameedi, {Faiq A.} and Goddard, {Andrew W.} and Potkin, {Steven G.} and Donald Black and Mustaq Jameel and Kishore Desagani and Woods, {Scott W.}",
year = "2001",
month = "8",
day = "5",
doi = "10.1016/S0165-1781(01)00265-7",
language = "English (US)",
volume = "103",
pages = "1--14",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Fluvoxamine in the treatment of panic disorder

T2 - A multi-center, double-blind, placebo-controlled study in outpatients

AU - Asnis, Gregory M.

AU - Hameedi, Faiq A.

AU - Goddard, Andrew W.

AU - Potkin, Steven G.

AU - Black, Donald

AU - Jameel, Mustaq

AU - Desagani, Kishore

AU - Woods, Scott W.

PY - 2001/8/5

Y1 - 2001/8/5

N2 - Serotonergic mechanisms have been implicated in panic disorder, and several preliminary studies suggest that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is helpful in its treatment. This 8-week double-blind parallel-group study compared fluvoxamine with a placebo in 188 patients with DSM-III-R defined panic disorder with or without agoraphobia. Efficacy assessments included a Daily Panic Attack Inventory, the Sheehan Disability Scale, the Clinical Anxiety Scale and the Clinical Global Impression Scale. When compared with the placebo, fluvoxamine produced highly significant improvements in most measures of the frequency and severity of panic disorder and in the more global aspects of disability and distress. Significant improvement was evident as early as week 1 for some panic variables. Fluvoxamine is a potent anti-panic agent with a relatively rapid onset of action.

AB - Serotonergic mechanisms have been implicated in panic disorder, and several preliminary studies suggest that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is helpful in its treatment. This 8-week double-blind parallel-group study compared fluvoxamine with a placebo in 188 patients with DSM-III-R defined panic disorder with or without agoraphobia. Efficacy assessments included a Daily Panic Attack Inventory, the Sheehan Disability Scale, the Clinical Anxiety Scale and the Clinical Global Impression Scale. When compared with the placebo, fluvoxamine produced highly significant improvements in most measures of the frequency and severity of panic disorder and in the more global aspects of disability and distress. Significant improvement was evident as early as week 1 for some panic variables. Fluvoxamine is a potent anti-panic agent with a relatively rapid onset of action.

KW - Agoraphobia

KW - Anxiety

KW - Selective serotonin reuptake inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0035812174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035812174&partnerID=8YFLogxK

U2 - 10.1016/S0165-1781(01)00265-7

DO - 10.1016/S0165-1781(01)00265-7

M3 - Article

C2 - 11472786

AN - SCOPUS:0035812174

VL - 103

SP - 1

EP - 14

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1

ER -